Crossmark

Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging

Crossref DOI link: https://doi.org/10.14283/jpad.2021.56

Published Print: 2021-10

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Lowe, S.L.

Duggan Evans, C.

Shcherbinin, S.

Cheng, Y.-J.

Willis, B.A.

Gueorguieva, I.

Lo, A.C.

Fleisher, A.S.

Dage, J.L.

Ardayfio, P.

Aguiar, G.

Ishibai, M.

Takaichi, G.

Chua, L.

Mullins, G.

Sims, John R.
License Information

Text and Data Mining valid from 2021-10-01

Text and Data Mining valid from 2021-10-01

Version of Record valid from 2021-09-21
More Information

This article is maintained by: Elsevier

Article Title: Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging

Journal Title: The Journal of Prevention of Alzheimer's Disease

CrossRef DOI link to publisher maintained version: https://doi.org/10.14283/jpad.2021.56

Content Type: article

Copyright: Copyright © 2021 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS